Isis sees positive data in Phase II diabetes trial

Isis Pharmaceuticals says that data for its mid-stage trial of the diabetes drug Isis 113715 demonstrated improved blood sugar control in newly diagnosed patients but that blood sugar was not significantly improved. Patients taking 200 milligrams of the drug per week improved fasting blood glucose, fasting serum glucose and bad cholesterol. However, they did not see a significant improvement in hemoglobin A1c levels. The therapy, a second generation antisense drug, inhibits a protein that blocks insulin.

- read the AP report on Isis

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.